Breye Therapeutics closes €67.5M Series A led by Mission BioCapital and Novo Holdings

Breye Therapeutics, based in Hørsholm, Denmark, raised €67.5M in a Series A round in October 2026. The round was led by Mission BioCapital and Novo Holdings. Other investors included Sound Bioventures, Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, and Pappas Capital. Breye Therapeutics is developing oral therapeutics for the early treatment of retinal diseases such as diabetic retinopathy and age-related macular degeneration.

Round size compared to peers

This €67.5M Series A round is larger than 94% of 400 European Healthcare & Life Sciences Series A rounds from January 2025 to October 2026. The median round size in this group is €11M, the top quarter starts at €20M, and the top tenth starts at €46M.

Investor activity

Mission BioCapital led this round. Novo Holdings also led and has participated in 90 rounds since January 2025, including 27 at the Series A stage.

Innovestor joined this round among 117 rounds since January 2025, with 25 at the Series A stage.

Modi Ventures participated in 9 rounds since January 2025, 4 of which were Series A.

Sound Bioventures took part in 4 rounds since January 2025, 2 at Series A.

Previous rounds

Breye Therapeutics previously raised €4M in a Seed round in November 2022, 47 months before this Series A.

Share cards

One image per company in this round, free to post. Breye Therapeutics, Novo Holdings, Innovestor, Modi Ventures, Sound BioVentures.

Sources

Round amount and investors: eu-startups.com. Comparisons and investor track records: Brouky investment data, January 2025 to 2026-10.